Rhythm Pharmaceuticals/RYTM

$40.33

-5.28%
-
1D1W1MYTD1YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Ticker

RYTM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Meeker

Employees

226

Headquarters

Boston, United States

RYTM Metrics

BasicAdvanced
$2.46B
Market cap
-
P/E ratio
-$3.19
EPS
1.94
Beta
-
Dividend rate
$2.46B
1.93587
$52.57
$15.50
601.51K
5.584
5.428
62.526
62.526
-51.64%
-85.1%
-59.55%
31.754
14.118
15.109
227.56%
8.74%

What the Analysts think about RYTM

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
46.02% upside
High $80.00
Low $49.00
$40.33
Current price
$58.89
Average price target

RYTM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-171.9% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$24.2M
7.56%
Net income
$-41.6M
-5.67%
Profit margin
-171.9%
-12.3%

RYTM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.29%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.92
-$0.82
-$0.76
-$0.70
-
Expected
-$0.90
-$0.79
-$0.74
-$0.70
-$2.16
Surprise
1.71%
3.16%
2.78%
0.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rhythm Pharmaceuticals stock?

Rhythm Pharmaceuticals (RYTM) has a market cap of $2.46B as of April 14, 2024.

What is the P/E ratio for Rhythm Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of April 14, 2024.

Does Rhythm Pharmaceuticals stock pay dividends?

No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Rhythm Pharmaceuticals dividend payment date?

Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.

What is the beta indicator for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (RYTM) has a beta rating of 1.94. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Rhythm Pharmaceuticals stock price target?

The target price for Rhythm Pharmaceuticals (RYTM) stock is $58.89, which is 46.02% above the current price of $40.33. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rhythm Pharmaceuticals stock

Buy or sell Rhythm Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing